Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT ID: NCT02629796
Last Updated: 2023-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
44 participants
OBSERVATIONAL
2014-04-16
2021-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcriptome Analysis of the Peripheral Blood in CIDP
NCT02404298
Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
NCT02892890
Study of CIDP Patients During IVIG Treatment
NCT00305266
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
NCT03779828
Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT02465359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CIDP treated (IVIG)
patients with a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to European criteria, treated with IVIG (intravenous immunoglobulin as a first line of treatment) as a usual treatment
CIDP treated (IVIG)
usual treatment with intravenous immunoglobulin
control
healthy subjects
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CIDP treated (IVIG)
usual treatment with intravenous immunoglobulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* first line of treatment
* treatment with intravenous immunoglobulin required
* healthy subjects matched for age and gender
Exclusion Criteria
* uncontrolled diabetes, monoclonal spike with anti-ganglioside activity, anti myelin-associated glycoprotein antibodies, HIV infection, HBV infection, HCV infection, connective tissue disease, hemopathy, evolutive disease)
For healthy subjects:
any chronic or autoimmune disease
For all subjets viral or bacterial infection in the last 30 days chemotherapy in the last 5 years immunosuppressive therapy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Bordeaux, service de Neurologie
Bordeaux, Aquitaine, France
CHU Nantes, Laboratoire d'explorations fonctionnelles
Nantes, Loire Atlantique, France
CHU de Brest
Brest, , France
CHU de CAEN
Caen, , France
Service de Neurologie Hopital du Kremlin Bicêtre
Le Kremlin-Bicêtre, , France
CHRU Lille
Lille, , France
Service de Neurologie, CHU Limoges,
Limoges, , France
Hôpital Neurologique HCL, Lyon-Bron
Lyon, , France
CHU de NIMES
Nîmes, , France
Service de Physiologie Clinique - Explorations Fonctionnelles, Hôpital Lariboisière
Paris, , France
Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild
Paris, , France
Centre Hospitalier Intercommunal de Poissy/Saint-Germain-en-Laye
Poissy, , France
CHU de Poitiers
Poitiers, , France
CHU de ROUEN
Rouen, , France
Centre Hospitalier de Saint-Denis
Saint-Denis, , France
Service de Neurologie CHU St Etienne
Saint-Etienne, , France
Service de Neurologie, CHU de Strasbourg
Strasbourg, , France
CHU Henri Mondor
Créteil, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGN_2013-9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.